Estimativas de Nível Crítico de Cobertura Vacinal contra o SARS-CoV-2 em Sergipe

Authors

  • Paulo Ricardo MARTINS-FILHO
  • Diego Moura TANAJURA
  • Adriano Antunes de Souza ARAÚJO
  • Lucindo José QUINTANS-JÚNIOR
  • Walderi Monteiro da SILVA-JÚNIOR
  • Victor Santana SANTOS

Abstract

On January 17, 2020, the Brazilian Health Surveillance Agency (ANVISA) approved the emergency use of CoronaVac® and Covishield® vaccines in Brazil. However, the proportion of the population to be vaccinated against SARS-CoV-2 is unclear, leading to uncertainties about the strategic planning of immunization programs. Faced with the need to project the number of people who would need to be vaccinated to achieve herd immunity against the new coronavirus, we investigated the critical level of vaccine coverage for Sergipe. This analytical study considered three parameters to estimate the critical level of vaccine coverage: a) vaccine efficacy, b) the basic reproduction rate of the virus (R0) and c) the estimated population aged ≥18 years for the Sergipe state in 2021. Based on the current efficacy of CoronaVac® vaccine and using a basic reproduction rate between 1,5 and 2,0, it would be necessary to immunize 1,1 million to 1,7 million people in Sergipe. For Covishield® vaccine, using the same the parameter, except for vaccine efficacy, the estimated population to be immunized would be 900,000 to 1,4 million people. The preliminary results of this study are important to guide policymakers in vaccination programs against SARS-CoV-2 in Sergipe State. 

Downloads

Download data is not yet available.

Published

2021-01-24

Issue

Section

Artigo